

Hikma Board Appoints Cynthia Schwalm as Director

London, 12 March 2019 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma) announces the appointment of Cynthia Schwalm as an independent non-executive director effective 1 June 2019.

"I am very pleased that Cynthia will be joining the Hikma Board. She brings extensive, proven experience in providing strong leadership through transformation," said Said Darwazah, Executive Chairman. "Her extensive commercial and leadership experience in the pharmaceutical and biotech industries, as well as her experience as a healthcare practitioner will bring a fresh perspective to the board and our next stage of growth."

Most recently, Cynthia was President and CEO of the North American divisions of the global pharmaceutical companies Ipsen and Eisai, and also held leadership positions at Amgen and Johnson & Johnson. Cynthia is a non-executive director of Caladrius Biosciences Inc., Kadman Group, and G1 Therapeutics Inc., where she chairs the Compensation Committee.

She is a member of the National Association of Corporate Directors and an angel investment group associated with the University of North Carolina, and for nearly a decade she served on the Women's Leadership Advisory Board at Harvard University's Kennedy School of Government.

Cynthia holds a BSN from the University of Delaware and EMBA from Wharton at the University of Pennsylvania.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary
Susan Ringdal, EVP Strategy and Global Affairs

+44 (0)20 7399 2772
+44 (0)20 7399 2760

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.